摘要
合规管理作为企业自主性治理的重要手段,能够有效提高企业合规经营的能力进而有助于避免企业乃至全社会的经济损失,具有合规风险防控作用。促进医药企业加强合规管理,有利于夯实企业主体责任,实现从源头控制药品安全风险,进一步提升药品安全治理效能。因此,为了推进医药企业加强合规建设,本文对国外企业合规管理发展历程中的外部促进因素与企业开展合规管理的内在驱动力进行系统剖析;并基于动机理论分析框架,对国外企业合规管理促进机制进行分析总结;最后基于我国医药行业发展现状,对加强我国医药企业合规建设的思路与方法提出若干思考。
Compliance management system,as an important means of corporate self-governance,can effectively improve the ability of compliance level and thus help to avoid economic losses of enterprises and even the whole society,which has the role of compliance risk prevention and control.Promoting pharmaceutical companies to strengthen compliance management,is conducive to consolidate the main responsibility of enterprises to realize the control of drug safety risks at source,and further enhance the effectiveness of drug safety governance.Therefore,in order to promote the compliance construction of pharmaceutical enterprises,this paper systematically analyzes the external stimuli in the foreign development process of enterprises compliance management and the internal driving forces.And based on the analysis framework of motivation theory,the foreign enterprises compliance management promotion mechanism is analyzed and summarized.Finally,based on the China's pharmaceutical industry reality,some thoughts on strengthening the compliance construction of China's pharmaceutical enterprises are put forward.
作者
赵艳蛟
伍琳
陈永法
ZHAO Yanjiao;WU Lin;CHEN Yongfa(The Research Center of National Drug Policy&Ecosystem,China Pharmaceutical University,Nanjing 211198)
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2021年第7期964-970,共7页
Chinese Journal of Pharmaceuticals
关键词
企业合规
合规管理
合规建设
促进机制
医药企业
corporate compliance
compliance management
compliance building
promotion mechanism
pharmaceutical enterprises
作者简介
赵艳蛟(1987-),女,博士研究生,专业方向:医药政策与法规。E-mail:zyj15110@163.com;通信联系人:陈永法(1965-),男,教授,博士生导师,从事国内外药事法规及药品评价研究。E-mail:cyf990@163.com。
